Provider Biography
Dr. Jing Xi is a board-certified medical oncologist who joined Rocky Mountain Cancer Centers in 2022. Her clinical practice is dedicated to the care of patients with breast cancer, and she is committed to providing inclusive, compassionate care to all individuals, including those from the LGBTQ+ community and transgender patients. Her clinical and research interests are in molecular mechanisms of resistance to targeted therapy in metastatic breast cancer. She has contributed extensively to breast cancer research, including authoring and co-authoring peer-reviewed journal articles, oncology conference abstracts, and oncology book chapters. In addition to being actively involved in clinical research, Dr. Xi remains up to date on the most recent treatment advancements and cutting-edge therapies.
Dr. Xi’s goal at each clinic visit is to help navigate the cancer care journey together with her patients by guiding patients through their diagnosis and providing clear and comprehensive education on treatment options, including the latest clinical trials. This is to make sure that her patients can feel confident making informed decisions about their care.
Dr. Xi is an active member of several weekly tumor boards and multi-disciplinary clinics, where she works closely with other cancer specialists including breast imaging, surgical oncology, radiation oncology, and plastic surgery, to review patient cases, share knowledge, and determine the best possible treatment for each patient. This collaborative approach helps to deliver the highest quality of cancer care.
As a women’s health specialist, Dr. Xi also specializes in treating gynecologic cancers. As a board-certified hematologist, Dr. Xi also treats non-cancerous (benign) blood disorders including bleeding disorders, clotting disorders, and iron deficiency anemia.
Provider Specialties
- Blood Disorders
- Anemia
- Antiplatelet and Anticoagulant Management
- Bleeding & Clotting Disorders
- Iron Deficiency
- Pregnancy -Related Blood Disorders
- Surgical Clearances
- Thrombocytopenia
- Breast Cancers
- Overview
- Atypical Ductal Hyperplasia
- Atypical Lobular Hyperplasia
- Ductal Carcinoma in Situ (DCIS)
- HER2+ Breast Cancers
- Inflammatory Breast Cancer
- Invasive Breast Cancer (IDC/ILC)
- Lobular Carcinoma in Situ (LCIS)
- Metastatic Breast Cancer
- Paget Disease of the Breast
- Triple-Negative Breast Cancer
- Cancer Genetics
- Clinical Research
- High Risk Breast Cancer Prevention
- Gynecologic Cancers
- Cervical Cancer
- Ovarian Cancer
- Uterine Cancer
- Vaginal Cancer
- Vulvar Cancer
Languages Spoken
- Chinese (Standard Mandarin)
- English
Introduction Video
Care Philosophy
I am dedicated to delivering personalized care to improve patient outcomes and quality of life. I offer a tailored therapeutic approach based on each patient’s specific tumor biology and side-effect profile, which yields better treatment response and tolerability. I integrate the latest advances in science into patient care. I take care of my patients as a whole person, including not only their physical health, but also emotional health, and in some patients, reproductive health during their treatment with chemotherapy and endocrine therapy.
Care Team
Locations
Centennial
Centennial, CO 80112
Englewood - HCA HealthOne Swedish
Englewood, CO 80113
Littleton
Littleton, CO 80120
Reviews
Education
Fellowship
Medical Oncology & Hematology, Washington University, St. Louis, MO
Residency
Internal Medicine, St. Luke’s Hospital, Chesterfield, MO
Medical School
Fudan University, Shanghai, China
Board Certifications
Hematology
Internal Medicine
Medical Oncology
Memberships
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
American Medical Association (AMA)
Chinese American Hematologist and Oncologist Network (CAHON)
European Society for Medical Oncology (ESMO)
Articles
Videos
Presentations
-
Show Presentations
-
Genomic Profiles of Early Progressors vs Exceptional Responders on CDK4/6i in ER+ HER2- Advanced Breast CancerKong, T., Thomas, S., Davis, A., Podany E., Xi, J., Ma, C., Clifton, K. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 10-13, 2024
Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer
Mardani, M., Noordeen, S., Clifton, K., Ma, C., Luo, J., Kobayashi , T., Xi, J., Bagegni, N., Ademuyiwa, F., Suresh, R., Frith, A., Davis, A., Bose, R., Peterson, L., Thomas, S., Tao, Y., Xiang, J., Xu, Y., Su, X., Weilbaecher, K. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 5-9, 2023Clifton, K., Thomas, SN., Luo J., Xi, J., Bagegni, NA., Ademuyiwa, FO., Suresh, R., Frith, A., Davis, AA., Bose, R., Weilbaecher, K., Hensing WL., Pluard T., Cristofanilli M., Han HS., Brufsky AM., Kalinsky K., Goel S., Wander SA., Peterson LL., Ma, CX. Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 6-10, 2022 [spotlight poster]
Xi, J., Luo, J., O’Sullivan, C., Chen, N., Stringer-Reasor, E., Ma, C., Campian, J. Phase II Study of the Combination of Liposomal Irinotecan and Pembrolizumab for Triple-Negative Breast Cancer with Brain Metastases. 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. Toronto, Canada. Aug 12-13, 2022
Xi, J., Harnden, K., Call, G., Mauer, E., Ronski, K., Luo, J., Ma, C*, and Vasan, N. Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 7-10, 2021
Brett, J., Dubash, T., Niemierko, A., Mariotti, V., Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Lloyd, MR., Spring, LM., Micalizzi, D., Onozato, M., Che, D., Brufsky, A., Kalinsky, K., Ma, CX., O’Shaughnessy, J., Han, HS., Iafrate, J., Maheswaran, S., Haber, DA., Bardia, A., Wander, SA. Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 7-10, 2021 [spotlight poster]
Xi, J., Bagegni, N., Ademuyiwa, F., Frith, A., Suresh, R., Roshal, A., Rigden, C., Hernandez-Aya, L., Peterson, L., Opyrchal, M., Clifton, K., Weilbaecher, K., Bose, R., Ma CX. Circulating tumor DNA mutation profile in relation to palbociclib efficacy in hormone receptor positive and HER2 negative metastatic breast cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 8-12, 2020
Wander, S., Han, H., Johnson, G., Lloyd, M., Mao, P., Nayar, U., Kowalski, K., Stein, C., Mariotti, Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Brufsky, A., Kalinsky, K., Ma, C., O’Shaughnessy, J., Wagle, N., Bardia, A. ESR1 mutation as a potential predictor of abemaciclib benefit following prior CDK4/6 inhibitor (CDK4/6i) progression in hormone receptor-positive (HR+) metastatic breast cancer (MBC): a translational investigation. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 8-12, 2020
Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C., Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C., O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. American Society of Clinical Oncology (ASCO) Meeting, Chicago, IL. May 31 – June 4, 2019. Same abstract published in JCO 2019; 37 (15_Suppl)
Xi, J.*, Oza, A.*, Thomas, S., Naughton, M., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Review of Palbociclib Efficacy and Benefit from Subsequent Treatments Following Palbociclib Progression in Patients with Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. Dec 5-9, 2017. Same abstract published
in AACR 2018; 78(4_Suppl)Tavris, D., Wang, C., Chu H., Xi J., Nie L., Jacobs S., Duggirala H., Pinnow E. Assessing Publication Bias from Clinical Studies of Coronary Artery Stents. International Society for Pharmacoepidemiology (ISPE) Annual Conference, Chicago, IL. Aug 14-17, 2011
Xi, J. An Overlooked Sexual Orientation Health Disparities in Female Breast Cancer Screening. The Michigan Meeting 2010: The Economy and Cancer Health Disparities, Ann Arbor, MI. May 20-22, 2010
-
Publications
-
Show Publications
-
Peer-Reviewed Journal Articles
Xi, J., Ma, C., O’Shaughnessy, J. Current Clinical Utility of ctDNA Testing in Breast Cancer: A Practical Approach. Journal of Clinical Oncology (JCO) Oncology Practice 20:1460-1470. Nov 2024 [PMID: 39531841]
Brett, J., Dubash, T., Johnson, G., Niemierko, A., Mariotti, V., Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Lloyd, M., Kambadadone, A., Spring, L., Micalizzi, D., Onozato, M., Che, D., Nayar, U., Brufksy, A., Kalinsky, K., Ma, C., O'Shaughnessy, J., Han, H., Iafrate, A., Ryan, L., Juric, D., Moy, B., Ellisen, L., Maheswaran, S., Wagle, N., Haber, D., Bardia, A., and Wander S. A gene panel associated with abemaciclib utility in ESR1-mutated breast cancer after prior CDK4/6-inhibitor progression. Journal of Clinical Oncology (JCO) Precision Oncology. 2023 [Accepted]
Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C., Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C., O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network (JNCCN) 2021 Mar 24:1-8: [Epub ahead of print]
Xi, J.*, Hassan, B.*, Katumba, R., Khaddour, K., Govindan, A., Luo, J., Huang, J., Campian, JL. The Predictive Value of Absolute Lymphocyte Counts on Tumor Progression and Pseudoprogression in Patients with Glioblastoma. BMC Cancer 2021 Mar 16:21(1): 285
Xi, J., Cynthia X. Ma. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor? Current Oncology Reports 2020; 22 (6): 57.
Xi, J.*, Oza, A.*, Thomas, S., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network (JNCCN) 2019; 17(2): 141-147.
Patel, D.*, Xi, J.*, Luo, J., Ma, C., Campian, J. Neutrophil to Lymphocyte Ratio as a Predictor of Survival in Patients with Triple-Negative Breast Cancer. Breast Cancer Research and Treatment 2019; 174(2): 443-452.
Yang, C.*, Xi, J.*, Sheikh, S., Hakim, A., Nadella, S., Dhital, S., MD; Meier, M., Nnanna, O., Meyers, D. A Scoring System for Prediction and Risk Stratification of CO2 Narcosis Among Hospitalized Patients. Emergency Medicine 2018; 8(2):368.
Book Chapters
Xi, J., Ma, C., Clifton, K. Chapter 13. Breast Cancer. The Washington Manual of Oncology. 4th edition. 2021
Committee on Review of California Institute for Regenerative Medicine (CIRM) (Group Author). The California Institute for Regenerative Medicine: Science, Governance, and the Pursuit of Cures. 2012. Washington, DC: The National Academies Press.
Committee on Advancing Pain Research, Care, and Education (Group Author). Relieving Pain in America – A Blueprint for Transforming Prevention, Treatment, and Research. 2011. Washington, DC: The National Academies Press.
-
Our providers accept all of the following insurances:
- Aetna
- Anthem BCBS Colorado
- Apostrophe Health
- benefitSMART
- Carrum
- Cigna
- Claritev Multiplan / PHCS
- Colorado Access
- First Health
- Humana Medicare Advantage
- *Kaiser (depending on market)
- Medicare
- Medicaid
- Optum Health / Optum Care CO
- PHPprime
- Rocky Mountain Health Plans Medicaid Prime, CHP+, Valley, Monument Tier 2 & CO Doctors Plan
- SMS
- Select Health Colorado Public Option (Exchange) and Medicare Advantage (MA)
- TRICARE/HealthNET
- United Healthcare
Awards
